Insmed (INSM) Net Equity Issued and Repurchased (2011 - 2025)
Insmed (INSM) posted quarterly Net Equity Issued and Repurchased of -$256000.0 for Q3 2025, down 100.07% year-over-year from $371.0 million in Q3 2024, and down 2033.33% quarter-over-quarter from -$12000.0 in Q4 2024.
Insmed (INSM) Net Equity Issued and Repurchased (2011 - 2025) Analysis & Trends
Insmed's Net Equity Issued and Repurchased history runs 11 years deep, the most recent figure standing at -$256000.0 for Q3 2025.
- In Q3 2025, Net Equity Issued and Repurchased fell 100.07% year-over-year to -$256000.0; the TTM figure through Dec 2025 stood at $370.7 million (down 23.63% YoY), while the FY2025 annual figure was $823.3 million, down 24.06% from the prior year.
- Net Equity Issued and Repurchased for Q3 2025 stood at -$256000.0, down from -$12000.0 in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $371.0 million in Q3 2024, with the low at -$256000.0 in Q3 2025.
- The 4-year median for Net Equity Issued and Repurchased is $73.9 million (2022), against an average of $129.6 million.
- The sharpest annual moves came in 2023 and 2025: Net Equity Issued and Repurchased tumbled 55.77% in 2023, then sank 100.07% in 2025.
- Insmed's Net Equity Issued and Repurchased stood at $258.8 million in 2022, then sank by 55.77% to $114.5 million in 2023, then sank by 100.01% to -$12000.0 in 2024, then plunged by 2033.33% to -$256000.0 in 2025.
- Business Quant data shows INSM's Net Equity Issued and Repurchased at -$256000.0 in Q3 2025, -$12000.0 in Q4 2024, and $371.0 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -256,000.00 |
| Sep 30, 2025 | -256,000.00 |
| Dec 31, 2024 | -12,000.00 |
| Dec 31, 2024 | -12,000.00 |
| Sep 30, 2024 | 370.98 Mn |
| Sep 30, 2024 | 370.98 Mn |
| Dec 31, 2023 | 114.46 Mn |
| Dec 31, 2023 | 114.46 Mn |
| Dec 31, 2022 | 258.77 Mn |
| Dec 31, 2022 | 258.77 Mn |
| Sep 30, 2022 | 33.38 Mn |
| Sep 30, 2022 | 33.38 Mn |
| Dec 31, 2020 | 1,000.00 |
| Dec 31, 2020 | 1,000.00 |
| Sep 30, 2020 | -47,000.00 |
| Sep 30, 2020 | -47,000.00 |
| Sep 30, 2019 | -104,000.00 |
| Sep 30, 2019 | -104,000.00 |
| Sep 30, 2017 | 377.70 Mn |
| Sep 30, 2017 | 377.70 Mn |